PPARγ and RXRα Ligand Binding Assays: Corexit Components

HEK293T cells were triple transfected with PPARγ ligand binding domain expression vectors, firefly luciferase reporter vectors and renilla luciferase control vectors. Cells were then exposed to positive and negative control ligands (Rosiglitazone and DMSO respectively) and serial dilutions of DOSS, ICP:PG:DOSS, ICP:PG and Span80 treatments. Activation of the PPARγ binding domain was observed in DOSS containing treatments only, exhibiting a dose response curve indicating obesogenic potential DOSS.

HEK293T细胞（HEK293T cells）被三重转染过氧化物酶体增殖物激活受体γ（PPARγ）配体结合结构域表达载体（PPARγ ligand binding domain expression vectors）、萤火虫荧光素酶报告基因载体（firefly luciferase reporter vectors）以及海肾荧光素酶对照载体（renilla luciferase control vectors）。随后将细胞分别暴露于阳性对照配体罗格列酮（Rosiglitazone）、阴性对照配体二甲基亚砜（DMSO），以及系列稀释的DOSS、ICP:PG:DOSS、ICP:PG及Span80处理组。实验结果显示，仅在含DOSS的处理组中可检测到PPARγ结合结构域的激活，且该激活呈现剂量响应曲线，表明DOSS具备致肥胖潜力。